PRL-8-53 10mg – 60 capsules

PRL-8-53 10 mg — 60 oral research capsules. PRL-8-53 occupies one of the most distinctive niches in the entire nootropic literature: it is the subject of a single 1978 controlled human clinical trial — but that trial reported what remains, more than four decades later, the largest single-dose memory-enhancement effect ever documented in a placebo-controlled human study. In Hansl & Mead’s double-blind crossover study of 47 healthy adults, a single oral 5 mg dose of PRL-8-53 produced statistically significant improvements in word-list learning, with the effect amplified up to ~108 % above baseline in older subjects with lower initial recall scores. The molecule has remained essentially unstudied since, making it one of the most intriguing orphan compounds in cognitive-enhancement research.

Research Overview

PRL-8-53 is a benzylamino-ethyl-benzoate small molecule synthesized in the early 1970s by Nikolaus Hansl at Creighton University, originally as part of a structure-activity program around acetylcholine releasing agents [1]. In the only published human clinical trial — Hansl & Mead, 1978 — a single 5 mg oral dose of PRL-8-53 was administered in a placebo-controlled, double-blind crossover design to 47 healthy adults aged 21–69, with assessment of recall on standardized word-list learning tasks 24 hours post-administration [1]. The reported effect was striking: a statistically significant overall improvement in delayed recall, with the most pronounced effects observed in the older subjects and the lower-baseline performers — in whom the magnitude of improvement reached approximately 108 % of placebo-condition recall [1]. Mechanistically, PRL-8-53 has been proposed to act as a partial cholinergic enhancer with concomitant dopaminergic and serotonergic modulation, but no formal in-depth pharmacology study has ever been published [2]. The compound has remained essentially orphaned in academic research since the original 1978 paper — a striking case of a molecule with extraordinary single-trial human data that has never undergone the contemporary characterization it appears to deserve [2,3].

Primary Research Areas

• Memory and recall enhancement — the only molecule in the entire nootropic literature with a peer-reviewed double-blind placebo-controlled human study showing >100 % memory enhancement in lower-baseline performers [1].
• Cholinergic-dopaminergic interaction — proposed to act as a partial cholinergic enhancer with dopaminergic and serotonergic modulation, providing a unique mechanistic profile [2].
• Single-dose acute cognitive enhancement — the original Hansl & Mead protocol used a single oral dose, distinguishing PRL-8-53 from chronic-dosing nootropics [1].
• Aging and lower-baseline-performer pharmacology — the original effect was greatest in older, lower-baseline subjects — suggestive of a rescue-of-impaired-systems mechanism rather than supra-baseline enhancement [1,3].
• Orphan compound research — an extraordinary 47-year publication gap makes PRL-8-53 one of the most intriguing orphan molecules in cognitive-enhancement chemistry [2,3].

References

1. Hansl NR, Mead BT. PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Psychopharmacology (Berl). 1978;56(3):249–253.
2. Hansl NR. New compounds with promnesic effects. Adv Behav Biol. 1974;10:329–337.
3. Giurgea CE. The nootropic concept and its prospective implications. Drug Dev Res. 1982;2(5):441–446.